Management of Gliomas: Individualized Treatment Options

Presenter: Louis Burt Nabors
Restricted access

Optimizing treatment for patients with low-grade gliomas should focus on the role of radiation and chemotherapy, as well as the prognostic impact of molecular diagnostics (1p/19q and IDH status). For anaplastic oligodendroglioma, focus should be placed on molecular markers (particularly 1p/19q status) and combination treatment with chemotherapy (temozolomide or PCV [procarbazine, lomustine, and vincristine]) and radiation. For patients with malignant glioblastomas, the role of methylguanine methyl-transferase (MGMT) methylation status has become increasingly important to treatment decisions. MGMT methylation status should be considered in elderly patients and/or those with low performance status (methylated patients benefit from temozolomide) and a hypofractionated radiation schedule should be used.

Disclosures: Dr. Nabors has disclosed that he is a scientific advisor for AbbVie, Inc., BTG Pharmaceuticals, Karyopharm Therapeutics, Blue Earth Diagnostics, and Kiyatec.

Correspondence: Louis Burt Nabors, MD, O’Neal Comprehensive Cancer Center at UAB, 510 20th Street South, FOT 1020, Birmingham, AL 35294. Email: bnabors@uab.edu
  • 1.

    Yabroff KR, Lund J, Kepka D, . Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20:20062014.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Ostrom QT, Gittleman H, Xu J, . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol 2016;18(Suppl 5):v175.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Cairncross G, Wang M, Shaw E, . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337343.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    van den Bent MJ, Brandes AA, Taphoorn MJB, . Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 2013;31:344350.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Shaw EG, Wang M, Coons SW, . Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012;30:30653070.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Buckner JC, Shaw EG, Pugh SL, . Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 2016;374:13441355.

  • 7.

    Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, . Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:24812498.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Stupp R, Mason WP, van den Bent MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987996.

  • 9.

    Hegi ME, Diserens A, Gorlia T, . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:9971003.

  • 10.

    Perry JR, Laperriere N, O’Callaghan CJ, . Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017;376:10271037.

  • 11.

    Wen PY, Macdonald DR, Reardon DA, . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:19631972.

    • Crossref
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 300 300 300
PDF Downloads 84 84 84
EPUB Downloads 0 0 0